(Q52246434)

28 April 2018

title

Impact of managed care on the treatment of atrial fibrillation. (English)

1 reference

28 April 2018

1 reference

C M Pratt

1

1 reference

28 April 2018

language of work or name

English

0 references

publication date

1 March 1998

1 reference

28 April 2018

American Journal of Cardiology

published in

1 reference

28 April 2018

volume

81

1 reference

28 April 2018

issue

5A

1 reference

28 April 2018

page(s)

30C-34C

1 reference

28 April 2018

Management of atrial fibrillation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Veterans Affairs congestive heart failure antiarrhythmic trial. CHF STAT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Stroke Prevention in Atrial Fibrillation Study. Final results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900184-2

10.1016/S0002-9149(98)00184-2

7 January 2021

Identifiers

DOI

1 reference

28 April 2018

1 reference

28 April 2018